Related Stories
![logo](https://udic.es/wp-content/uploads/2017/07/logo.png)
21 de November de 2023
Trial on LRRK2 mutation in Parkinson’s disease is about to be completed. Our Clinical Trials…
Posted in: Uncategorised
![Area privada5](https://udic.es/wp-content/uploads/2017/11/Area-privada5-262x201.jpg)
16 de January de 2023
On Epiphany, the U.S. Food and Drug Administration approved a new drug for early-stage Alzheimer’s…
![Area privada1](https://udic.es/wp-content/uploads/2017/11/Area-privada1-262x201.jpg)
3 de June de 2021
The General University Hospital of Catalonia is the first recognized center in Europe to evaluate…
Posted in: Alzeimer, Uncategorised
![Blogudic1](https://udic.es/wp-content/uploads/2019/03/Blogudic1-262x201.jpg)
![logo](https://udic.es/wp-content/uploads/2017/07/logo.png)
22 de July de 2020
The FDA has approved the use of sublingual apomorphine (KYNMOBI) in motor blocks, in Parkinson’s…
Posted in: Parkinson, Uncategorised
![Proyectos2](https://udic.es/wp-content/uploads/2017/11/Proyectos2-262x201.jpg)
12 de December de 2019
![UDICEQUIPOMEDICO3](https://udic.es/wp-content/uploads/2018/11/UDICEQUIPOMEDICO3-262x201.jpg)
5 de November de 2019
The Pasqual Maragall Foundation develops a method based on magnetic resonance imaging It allows to…
Posted in: Alzeimer, Uncategorised
![Proyectos2 1](https://udic.es/wp-content/uploads/2017/11/Proyectos2-1-262x201.jpg)
20 de September de 2019
Our team participated in a phase II clinical trial, with an antiamyloid monoclonal antibody in…
Posted in: Alzeimer